Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study

Background Rabies vaccines are lifesaving in human post animal exposure. However, the compliance to the complete course of vaccine is found to be only 60%. Hence, there is a need for safe and immunogenic, shorter course vaccine that can enhance the compliance and effectively prevent the disease. Obj...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ravish H S, Akash Khobragade, Durga Satapathy, Monica Gupta, Surendra Kumar, Vinay Bhomia, Ramasubramanian V, Maharshi Desai, Ashok Dilipkumar Agrawal
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2021-11-01
Edice:	Human Vaccines & Immunotherapeutics
Témata:	recombinant rabies g protein vaccine noninferiority safety immunogenicity simulated postexposure prophylaxis
On-line přístup:	http://dx.doi.org/10.1080/21645515.2021.1957413
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!